25th February 2026
Jellagen (UK) announces Strategic Partnership with Royal Biologics to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market
Jellagen (UK) announces Strategic Partnership with Royal Biologics to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market
Jellagen (UK) and Royal Biologics (Hackensack, NJ – USA), a leader in advanced wound care, orthobiologics, and regenerative medicine, are pleased to announce a transformative investment and strategic partnership to bring to market Jellagen’s Collagen Type Zero: a next-generation, jellyfish-derived, sustainable biomaterial.
A New Era of Collagen Science
Today’s collagen biomaterials are dominated by mammalian sources such as bovine, porcine, and rodent tissue. These sources carry inherent risks of disease transmission, viral contaminants, and ethical or religious sourcing concerns. Jellagen’s Collagen Type Zero, derived sustainably from the jellyfish Rhizostoma pulmo, avoids these limitations and represents a paradigm shift in collagen chemistry and tissue regeneration.
Salvatore Leo, CEO and founder of Royal Biologics
“We are thrilled to announce our investment and strategic partnership with Jellagen UK. We are about to bring to the world what we believe is the most valuable collagen source on the planet. We are very impressed with the portfolio, patents and pipeline Jellagen’s scientific and R&D team have built over the last decade. Type Zero isn’t just a new product, it’s a new novel class of collagen. ”
Salvatore Leo will join Jellagen’s board of directors and act as strategic commercialization lead for Type Zero product launch.
Thomas-Paul Descamps, CEO of Jellagen
“The strategic partnership with Royal Biologics is a gamechanger in Jellagen’s journey. Royal Biologics’ investment will both fund our product portfolio development and provide us with unique and privileged access to US and global markets to deliver new healing solutions to patients. This partnership is a rewarding recognition of the milestones achieved by the team during this last 8 years.”
Dr Andrew Mearns-Spragg, CSO and Founder of Jellagen added
“We are so proud to have secured this partnership with Royal Biologics recognizing the huge potential in Jellagen’s Type Zero regenerative medicine platform and capabilities. It is very exciting to see how Royal Biologics are inspired by the potential of Type Zero technology to deliver significant new health innovation. We look forward to building an exciting and fruitful partnership. ”
About Royal Biologics
Royal Biologics is a global, clinically driven biologics and wound care company committed to delivering innovative regenerative solutions. The company focuses on patient-centered outcomes through advanced science, engineered devices, and a dedicated national field team to transform how wounds heal and tissues regenerate.
About Jellagen
Jellagen is a UK-based biomaterials company developing Collagen Type Zero, a revolutionary jellyfish-derived collagen platform with inherent characteristics ideal or tissue engineering, wound healing, and regenerative medicine applications. Visit jellagen.co.uk for more information.